Bidirectional Transport of Rhodamine 123 and Hoechst 33342, Fluorescence Probes of the Binding Sites on P-glycoprotein, across MDCK-MDR1 Cell Monolayers

Journal of Pharmaceutical Sciences

Volumn 93, Issue 5, 2004, Pages 1185-1194

  Tang, Fuxing ^a,b   Ouyang, Hui ^a   Yang, Jerry Z ^a,c   Borchardt, Ronald T ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c PFIZER INC   (United States)

Author keywords

Hoechst 33342; P glycoprotein; P gp binding site; Rhodamine 123

Indexed keywords

DAUNORUBICIN; ELACRIDAR; GLYCOPROTEIN P; HOE 33342; LIPOSOME; RHODAMINE 123;

ANIMAL CELL; ARTICLE; CELL MEMBRANE TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOG; DRUG PENETRATION; DRUG UPTAKE; KIDNEY CELL; MOLECULAR DYNAMICS; NONHUMAN; TRANSPORT KINETICS;

EID: 1942466493     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20046     Document Type: Article

References (24)

1. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. 1999. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39: 361-398.
2. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162.
3. Schinkel AH, Mol CA, Wagenaar E, van Deemter L, Smit JJ, Borst P. 1995. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer 31A:1295-1298.
4. Gottesman MM, Pastan I. 1993. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427.
5. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813.
6. Schinkel AH. 2001. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 500:365-372.
7. Schinkel AH, Smit JJ, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HP, Berns AJM, Borst P. 1994. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77:491-502.
8. Shapiro AB, Ling V. 1997. Positively cooperative sites for drug transport by P-glycoprotein with distinct drug specificities. Eur J Biochem 250:130-137.
9. Shapiro AB, Fox K, Lam P, Ling V. 1999. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone: Evidence for a third drug-binding site. Eur J Biochem 259:841-850.
10. Wang EJ, Casciano CN, Clement RP, Johnson WW. 2000. Two transport binding sites of P-glycoprotein are unequal yet contingent: Initial rate kinetic analysis by ATP hydrolysis demonstrates intersite dependence. Biochim Biophys Acta 1481: 63-74.
11. Wang EJ, Casciano CN, Clement RP, Johnson WW. 2001. Active transport of fluorescent P-glycoprotein substrates: Evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun 289:580-585.
12. Isenberg B, Thole H, Tummler B, Demmer A. 2001. Identification and localization of three photobinding sites of iodoarylazidoprazosin in hamster P-glycoprotein. Eur J Biochem 268:2629-2634.
13. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de Haas M, van Deemter L, Borst P, Varadi A, Sarkadi B. 1998. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. J Biol Chem 273:32167-32175.
14. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
15. Hamilton KO, Backstrom G, Yazdanian MA, Audus KL. 2001. P-glycoprotein efflux pump expression and activity in Calu-3 cells. J Pharm Sci 90:647-658.
16. Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabo K, Muller M, Hose CD, Monks A, Varadi A, Seprodi J, Sarkadi B. 1999. Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells. Biochem Pharmacol 58:571-586.
17. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS. 2001. Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther 299:620-628.
18. Kondratov RV, Komarov PG, Becker Y, Ewenson A, Gudkov AV. 2001. Small molecules that dramatically alter multidrug resistance phenotype by modulating the substrate specificity of P-glycoprotein. Proc Natl Acad Sci USA 98:14078-14083.
19. Li AP. 2001. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today 6: 357-366.
20. Gao J, Hugger ED, Beck-Westermeyer MS, Borchardt RT. 2000. Estimating intestinal mucosal permeation of compounds using Caco-2 cell monolayers. In: Doyle A, Griffiths JB, Newell DJ, editors. Current protocols in pharmacology. New York: John Wiley & Sons, pp 1-23.
21. Tang F, Horie K, Borchardt RT. 2002. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res 19:766-772.
22. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL. 1999. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27:827-834.
23. Taylor BJ, Olson DP, Ivy SP. 2001. Detection of P-glycoprotein in cell lines and leukemic blasts: Failure of select monoclonal antibodies to detect clinically significant P-gp levels in primary cells. Leuk Res 25:1127-1135.
24. de Bruin M, Miyake K, Litman T, Robey R, Bates SE. 1999. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. Cancer Lett 146:117-126.